[Role of advanced glycation end products and activation of PKC in diabetic retinopathy].
Kaji
Yuichi
Y
Department of Ophthalmology, University of Tsukuba, Institute of Clinical Medicine.
Oshika
Tetsuro
T
D000818:Animals; D017209:Apoptosis; D002199:Capillary Permeability; D049109:Cell Proliferation; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000209:etiology*; D015195:Drug Design; D042783:Endothelial Cells / Q000166:cytology; D017127:Glycation End Products, Advanced / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use; D008301:Maleimides / Q000494:pharmacology / Q000627:therapeutic use; D018384:Oxidative Stress; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D064546:Protein Kinase C beta; D012171:Retinal Vessels / Q000166:cytology / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D017127:Glycation End Products, Advanced; D007211:Indoles; D008301:Maleimides; D042461:Vascular Endothelial Growth Factor A; C099154:ruboxistaurin; D011493:Protein Kinase C; D064546:Protein Kinase C beta